Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A3 | P38919 | 2/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | RHEB | Q15382 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | TDO2 | P48775 | 2/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30310764 | 0.83 | EIF4A3 (0.53) | EIF4A3GRIN1RHEBKDM4EHPGD | |
| SCHEMBL3959096 | 0.83 | EIF4A3 (0.53) | EIF4A3GRIN1RHEBKDM4EHPGD | |
| SCHEMBL29425167 | 0.81 | IDO1 (0.61) | EIF4A3GRIN1FBP1KDM4EHPGD | |
| SCHEMBL22394993 | 0.81 | IDO1 (0.61) | EIF4A3GRIN1FBP1KDM4EHPGD | |
| SCHEMBL30817219 | 0.79 | IDO1 (0.58) | EIF4A3GRIN1RHEBKDM4EHPGD | |
| SCHEMBL24020852 | 0.79 | IDO1 (0.58) | EIF4A3GRIN1RHEBKDM4EHPGD | |
| SCHEMBL28899836 | 0.78 | GRIN1 (0.46) | EIF4A3GRIN1RHEBKDM4EHPGD | |
| SCHEMBL1144591 | 0.77 | KDM4E (0.77) | EIF4A3GRIN1FBP1RHEBKDM4E | |
| SCHEMBL27318461 | 0.74 | FEN1 (0.48) | EIF4A3GRIN1FBP1RHEBHPGD | |
| SCHEMBL8328414 | 0.72 | GLA (0.43) | FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | EIF4A3 608/4885GRIN1 4507/4885FBP1 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.